Table 1.

Number of isolated CTCs from SF samples and parameters of PCa in patients.

Patient Number	Age	Tumor Localization (Zone/Lobe)	n *	V **	n/V	TNM Stage	Gleason Score	PSA Level
1	42	Peripheral /right	217	2.1	103.3	T1cN0M0	7	10.8
2	69	Peripheral/right	321	1.6	200.6	T2cN0M0	9	23
3	56	Peripheral/left	238	2.3	103.5	T2cN0M0	7	8.5
4	61	Peripheral/left and right	289	3.5	82.6	T2cN0M0	6	6.3
5	51	Central	460	1.5	306.7	T1bN0M0	8	19
6	56	Peripheral/right	183	1.9	96.3	T1cN0M0	7	6.5
7	51	Peripheral/right	174	2.6	66.9	T2bN0M0	7	16
8	59	Transitory/left	357	3	119.0	T2bN0M0	8	32.4
9	62	Peripheral/left	187	2.7	69.3	T1cN0M0	7	4.1
10	50	Peripheral/right	63	0.5	126	T1cN0M0	7	8.9
11	67	Peripheral/left	145	1.9	76.3	T1cN0M0	6	2.3
12	70	Transitory/left	329	1.4	235	T1cN0M0	7	14.7
13	63	Peripheral/left	115	1.6	71.9	T1cN0M0	7	8.2
14	70	Peripheral/left	613	2.7	227	T2cN0M0	10	10.2
15	72	Peripheral/right	340	2.4	141.7	T2cN0M0	7	9.2

*—total number of PSMA+, CK+, GPC-1+ putative tumor cells in the patients’ SF samples. **—total volume of a patients’ SF samples.